Artificial intelligence is arguably delivering its greatest positive impact in healthcare. By mid-2024, the US Food and Drug Administration had cleared approximately 950 AI/ML-enabled medical devices, with roughly 100 new approvals each year, spanning hundreds of companies and clinical specialties. In November 2025 alone, the FDA approved four new AI diagnostic tools designed to work alongside doctors for early disease detection (FDA, 2024; Alation, 2025).
AI diagnostics are matching or exceeding human expert performance in several domains. A landmark 2020 study in Nature demonstrated that Google Health's AI system for breast cancer screening outperformed radiologists, reducing false negatives by 9.4% and false positives by 5.7% in a US dataset (McKinney et al., 2020). Earlier, a 2017 study by Esteva et al. in Nature showed that a deep learning algorithm could classify skin cancer with accuracy matching board-certified dermatologists (Esteva et al., 2017).
Drug discovery is being transformed. Traditionally, bringing a new drug to market takes 10–15 years and costs over $2.6 billion. AI is compressing these timelines dramatically. Insilico Medicine has developed 28 AI-designed drugs, with nearly half already at clinical stage. Their lead compound, ISM001-055 for idiopathic pulmonary fibrosis, showed positive Phase IIa results in 2024. Isomorphic Labs, a DeepMind spinoff, announced that its AI-designed drugs are set to enter human trials — a major milestone (PMC, 2025).
Major pharmaceutical companies are investing heavily. Eli Lilly invested $1 billion in a dedicated AI drug discovery laboratory with Nvidia. IBM and Moderna launched a quantum computing platform that screens drug candidates 10,000 times faster than traditional methods, identifying three promising cancer drug candidates in its first month of operation (Alation, 2025).
Microsoft's MedImageInsight Premium, launched in 2025, is a multimodal AI model for analyzing X-rays and pathology slides that delivers up to 15% higher accuracy than previous versions. Their CXRReportGen Premium system generates clinic-ready chest X-ray reports, reducing the burden on radiologists and speeding up diagnosis. The global AI in healthcare market, valued at $26.6 billion in 2024, is projected to reach $187 billion by 2030 (Nature Digital Medicine, 2025).
Key Sources
- McKinney S.M. et al. (2020). International evaluation of an AI system for breast cancer screening. Nature, 577, 89–94.
- Esteva A. et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542, 115–118.
- FDA (2024). Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices.
- PMC (2025). Transformative Role of AI in Drug Discovery and Translational Medicine.